Beta-Blockers in Patients with Myocardial Infarction and No Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Hassan Kawtharany, Abdallah Rayyan, Aseed Mestarihi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis of randomized controlled trials assessed β-blocker therapy versus no β-blocker therapy after myocardial infarction in patients with left ventricular ejection fraction (LVEF) >40%. Five trials included 19,826 participants. β-blockers were not associated with significant reductions in all-cause mortality (HR 0.98, 95% CI 0.85-1.13), cardiac mortality, unplanned coronary revascularization, or malignant ventricular arrhythmia. The analysis found trends toward lower risks of recurrent MI and new-onset heart failure, but neither was statistically significant.
Key findings
- All-cause mortality did not differ significantly with β-blockers (HR 0.98, 95% CI 0.85-1.13).
- β-blockers showed a trend toward lower MI risk (HR 0.88, 95% CI 0.77-1.00).
- New-onset heart failure showed a nonsignificant trend toward reduction (HR 0.82, 95% CI 0.63-1.07).
- No significant differences were found in cardiac mortality, revascularization, malignant ventricular arrhythmia, symptomatic atrioventricular block, or stroke.
Why it matters
The findings address uncertainty about β-blocker use after MI when LVEF is above 40%, a population distinct from patients with reduced LVEF, for whom β-blockers have an established role. Across the included randomized trials, the analysis did not demonstrate significant benefit for the assessed outcomes, while possible reductions in recurrent MI and heart failure remain uncertain.
What to keep in mind
The analysis included five trials, and the reported estimates for possible reductions in MI and new-onset heart failure were not statistically significant.